AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22588156
Drug: Tasisulam sodium
RxNorm normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasisulam sodium (LY573636 sodium) administered at a lower Cmax target dose of 380 µg/ml
Trial: 18716159
Drug: 50 mg/d
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/d quercetin for 2 weeks
Trial: 18716159
Drug: 100 mg/d
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/d quercetin for 2 weeks
Trial: 18716159
Drug: 150 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/d quercetin for 2 weeks
Trial: 15943544
Drug: Transdermal methylphenidate
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal methylphenidate (MPH) 12.5 cm²
Trial: 15943544
Drug: Transdermal methylphenidate
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal methylphenidate (MPH) 25.0 cm²
Trial: 15943544
Drug: Transdermal methylphenidate
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal methylphenidate (MPH) 37.5 cm²
Trial: 15943544
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (MPH + BMOD)
Trial: 12801361
Drug: Miconazole (Daktarin(R)
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole (Daktarin(R) gel oral)
Trial: 12801361
Drug: Gel of
RxNorm normalized name: ZINC OXIDE 160 mg in 1 g TOPICAL OINTMENT [Angel of mine Diaper Rash]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel of Punica granatum Linné (pomegranate)
Trial: 10591258
Drug: Contact laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact laser ablation of the prostate (CLAP) using Nd:YAG laser treatment
Trial: 8915274
Drug: Fast ingestion
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast ingestion group with 20 mg of oral metoclopramide
Trial: 8915274
Drug: Standard ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ingestion group without additional drugs
Trial: 30744092
Drug: Olive leaf
RxNorm normalized name: OLIVE LEAF
DrugBank: Olea europaea leaf (DB14745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive leaf extract (OLE) supplementation (100 mg oleuropein equivalent to 20 g of olive leaf) for nine weeks.
Trial: 28654312
Drug: T'ai chi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T'ai chi combined with health education twice weekly for 12 weeks
Trial: 19887279
Drug: Sugammadex (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (2 mg/kg after obtaining 2 responses, 4 mg/kg with post‐tetanic count between 1 and 3 responses, 12 to 16 mg/kg for rescue reversal)
Trial: 17383057
Drug: MF59-adjuvanted subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted subunit vaccine (Sub/MF59)
Trial: 12708121
Drug: Pranayam training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranayam training (nadishuddhi, mukh-bhastrika, pranav and savitri pranayams) for 20 minutes daily for 3 months
Trial: 9892329
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg warfarin
Trial: 30946887
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment (control)
Trial: 28029326
Drug: O-DHAP (Ofatumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O-DHAP (Ofatumumab 1,000 mg)
Trial: 28029326
Drug: R-DHAP (Rituximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-DHAP (Rituximab 375 mg/m2)
Trial: 26392096
Drug: Short-course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiotherapy (25 Gy in five daily fractions over 1 week)
Trial: 26392096
Drug: Commonly used
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commonly used radiotherapy (40 Gy in 15 daily fractions over 3 weeks)
Trial: 21765361
Drug: Standard amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard amino acid intake (1.5 g · kg(‐1) · day(‐1))
Trial: 21765361
Drug: High amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High amino acid intake (3.0 g · kg(‐1) · day(‐1))
Trial: 19357135
Drug: 1 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg/day low molecular weight heparin (LMWH)
Trial: 1928019
Drug: Relapse Prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relapse Prevention Therapy (RPT) among severe users
Trial: 7095565
Drug: Aspirin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (two tablets four times a day for 24 hours)
Trial: 7095565
Drug: Bufferin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bufferin (two tablets four times a day for 24 hours)
Trial: 7095565
Drug: Paracetamol (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (two tablets four times a day for 24 hours)
Trial: 7095565
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets four times a day for 24 hours)
Trial: 29794581
Drug: Both TDR
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both TDR and nonoperative treatment
Trial: 27078151
Drug: CHO+PROT (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO+PROT (0.8 g carbohydrate + 0.4 g protein·kg(‐1)·h(‐1))
Trial: 27078151
Drug: CHO (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (1.2 g carbohydrate·kg(‐1)·h(‐1))
Trial: 22445212
Drug: Medication (fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (fluoxetine or venlafaxine)
Trial: 1828415
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg etodolac twice daily (n = 112)
Trial: 1828415
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg piroxicam once daily (n = 108)
Trial: 31601842
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of pomegranate extract (PomX)
Trial: 26059264
Drug: Guideline-concordant prescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-concordant prescribing of ACE-inhibitors/statins in early clinics
Trial: 19139736
Drug: Intra-BM injection
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intra-BM injection (IBMI) of one UCB unit
Trial: 19139736
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) injection of one UCB unit
Trial: 11509937
Drug: 100 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/kg intravenous immunoglobulin
Trial: 11509937
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of intravenous immunoglobulin
Trial: 11509937
Drug: 250 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/kg and 500 mg/kg intravenous immunoglobulin
Trial: 7804585
Drug: Topical ibuprofen
RxNorm normalized name: ibuprofen Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ibuprofen cream
Trial: 3243930
Drug: Transdermally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermally administered scopolamine (TTS-scopolamine) with acute alcohol intake (BAC 80 mg/dL)
Trial: 3243930
Drug: Transdermally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermally administered scopolamine (TTS-scopolamine) with acute alcohol intake (BAC 130 mg/dL)
Trial: 3243930
Drug: Transdermally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermally administered scopolamine (TTS-scopolamine)
Trial: 25107900
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg IVT-AFL every 4 weeks (0.5q4)
Trial: 25107900
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg IVT-AFL every 4 weeks (2q4)
Trial: 25107900
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg IVT-AFL every 8 weeks (2q8)
Trial: 25107900
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab every 4 weeks (Rq4)
Trial: 24005242
Drug: Cognitive-behavioral prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral prevention (CBP) program consisting of 8 weekly 90-minute group sessions followed by 6 monthly continuation sessions.
Trial: 21439275
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid and vitamin B administration for 3 months in nondiabetic group
Trial: 21439275
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid and vitamin B administration for 3 months in diabetic group
Trial: 18513835
Drug: Oral bolus
RxNorm normalized name: phenylbutazone 1000 MG Oral Bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bolus (OB) feeding
Trial: 10735611
Drug: Terlipressin (2mg/iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (2mg/iv injection)
Trial: 1477649
Drug: rhGM‐CSF administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM‐CSF administered subcutaneously (s.c.)
Trial: 29465250
Drug: Esomeprazole intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole intravenous bolus every 12 hours for 72 hours with second look endoscopy
Trial: 29465250
Drug: Continuous high
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous high dose esomeprazole infusion for 72 hours
Trial: 25085607
Drug: High-level endurance
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-level endurance training combined with cognitive-behavioural therapy (CBT)
Trial: 25085607
Drug: Low-level exercise
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level exercise combined with cognitive-behavioural therapy (CBT)
Trial: 17345071
Drug: Levodopa 25
RxNorm normalized name: levodopa 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa 25 mg
Trial: 17345071
Drug: Levodopa 50
RxNorm normalized name: levodopa 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa 50 mg
Trial: 17345071
Drug: Levodopa 250
RxNorm normalized name: levodopa 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa 250 mg
Trial: 17345071
Drug: Levodopa 100
RxNorm normalized name: levodopa 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa 100 mg (1 x 100 mg)
Trial: 17345071
Drug: Levodopa 100
RxNorm normalized name: levodopa 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa 100 mg (3 x 100 mg over 3 hours)
Trial: 14699490
Drug: Adefovir 10
RxNorm normalized name: adefovir 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adefovir 10 mg daily + Lamivudine
Trial: 28878437
Drug: Intensive health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive health guidance using IoT devices (measuring daily activity, body weight, and blood pressure)
Trial: 24655119
Drug: IV alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV alcohol infusion to attain and clamp the breath alcohol concentration (BrAC) at 50 mg%
Trial: 2125864
Drug: Electric acupuncture
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electric acupuncture stimulation (Hegu and Neiguan) with intravenous Pethedine (1.3 mg/kg)
Trial: 2125864
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 5% Glucose during operation
Trial: 30670438
Drug: Rifapentine 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifapentine 1,200 mg once weekly
Trial: 30670438
Drug: Rifapentine 900
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 900 mg twice weekly
Trial: 30670438
Drug: Rifapentine 450
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 450 mg daily
Trial: 27348211
Drug: Stimulant +
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant + Risperidone
Trial: 27348211
Drug: Stimulant +
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant + Placebo
Trial: 27348211
Drug: Stimulant only
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant only (baseline)
Trial: 17991656
Drug: GOS/lcFOS supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOS/lcFOS supplementation (3 times/d with 3 g GOS/lcFOS at a ratio of 9:1)
Trial: 113810
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (quasi-control)
Trial: 31004676
Drug: Albiglutide liquid
RxNorm normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albiglutide liquid formulation (30 mg for 4 weeks, then 50 mg for 22 weeks)
Trial: 31004676
Drug: Albiglutide lyophilized
RxNorm normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albiglutide lyophilized formulation (30 mg for 4 weeks, then 50 mg for 22 weeks)
Trial: 31004676
Drug: Albiglutide liquid
RxNorm normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albiglutide liquid formulation
Trial: 31004676
Drug: Albiglutide lyophilized
RxNorm normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albiglutide lyophilized formulation
Trial: 25029908
Drug: Rituximab maintenance
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab maintenance therapy for 2 years after immunochemotherapy
Trial: 23438262
Drug: 60 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL/kg 0.9% saline bolus
Trial: 23438262
Drug: 20 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL/kg 0.9% saline bolus
Trial: 21425571
Drug: Ligustrazine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ligustrazine (2 mg/kg, intravenous dripping 30 min before auto-blood collection)
Trial: 19436018
Drug: Aspirin (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (alone or with dipyridamole)
Trial: 19436018
Drug: Aspirin (alone)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (alone)
Trial: 8872690
Drug: Lidocaine 1.5
RxNorm normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.5 mg/kg (Group LID)
Trial: 8872690
Drug: Esmolol 1
RxNorm normalized name: esmolol 10 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 1 mg/kg (Group E1)
Trial: 8872690
Drug: Esmolol 2
RxNorm normalized name: esmolol 20 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 2 mg/kg (Group E2)
Trial: 8872690
Drug: Lidocaine 1.5
RxNorm normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.5 mg/kg and Esmolol 1 mg/kg (Group LID-E1)
Trial: 8872690
Drug: Lidocaine 1.5
RxNorm normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.5 mg/kg and Esmolol 2 mg/kg (Group LID-E2)
Trial: 1504110
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg yohimbine orally
Trial: 6096626
Drug: Etomidate (0.26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.26 mg/kg)
Trial: 29074099
Drug: Long-acting pasireotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting pasireotide (60 mg intramuscularly every 28 days)
Trial: 29074099
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of long-acting pasireotide and everolimus
Trial: 16643262
Drug: BASO II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BASO II trial (treatment trial)
Trial: 26685849
Drug: Amoxicillin/metronidazole for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/metronidazole for 7 days
Trial: 23747646
Drug: Home-based treadmill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based treadmill training (6 times per week, twice daily for 10-20 minutes, for 6 weeks)
Trial: 20032102
Drug: rAAV2‐TNFR:Fc (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAAV2‐TNFR:Fc (1 x 10(11), 1 x 10(12), or 1 x 10(13) DNase‐resistant particles/ml joint volume)
Trial: 10759886
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy with continuous intravenous infusion of antithrombin III and two intraperitoneal instillations of fresh frozen human donor serum
Trial: 10759886
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy with antithrombin III and serum
Trial: 1639655
Drug: Chemohormonal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemohormonal therapy followed by local treatment and maintenance therapy
Trial: 19047976
Drug: Metronidazole 250
RxNorm normalized name: metronidazole 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 250 mg q.i.d., amoxicilline 1 gr b.i.d. and PPI standard dose (MAO)
Trial: 19047976
Drug: Tinidazole 500
RxNorm normalized name: tinidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 500 mg b.i.d., amoxicilline 1 gr b.i.d. and PPI standard dose (TAO)
Trial: 2865120
Drug: Metronidazole monotherapy
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole monotherapy
Trial: 2865120
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cortisone, salazosulfapyridine and metronidazole
Trial: 27432821
Drug: L-carnitine (990
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (990 mg twice daily) for 12 weeks
Trial: 20228983
Drug: Ketoconazole tablet
RxNorm normalized name: Ketoconazole Tablets
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole tablet (200 mg per day for 14 days)
Trial: 20228983
Drug: Topical ketoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketoconazole 2% in orabase (applied twice daily)
Trial: 20228983
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between ketoconazole tablet and topical ketoconazole
Trial: 12785457
Drug: Tramadol 75
RxNorm normalized name: traMADol 75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 75 mg plus acetaminophen 650 mg
Trial: 12785457
Drug: Tramadol/acetaminophen combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol/acetaminophen combination
Trial: 9527091
Drug: Soluble vascular
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble vascular cell adhesion molecule-1 (VCAM-1)
Trial: 8703648
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desipramine (DMI) 100 mg
Trial: 8703648
Drug: Local infusions
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infusions and/or systemic treatments
Trial: 370109
Drug: Desipramine hydrochloride
RxNorm normalized name: Desipramine Hydrochloride
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desipramine hydrochloride (150 mg daily)
Trial: 370109
Drug: Diazepam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (20 mg daily)
Trial: 10648337
Drug: Nimodipine 60
RxNorm normalized name: nimodipine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 60 mg
Trial: 1737074
Drug: Bright white
RxNorm normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright white light treatment (2000‐3000 lux)
Trial: 1737074
Drug: Dim red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim red light placebo control treatment
Trial: 6093524
Drug: Cefazolin 1
RxNorm normalized name: cefazolin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 1 g three times daily
Trial: 27027655
Drug: 5-mg once-yearly
RxNorm normalized name: lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-mg once-yearly infusions of zoledronic acid